Skip Nav Destination
1-3 of 3
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Five-year outcomes for frontline brentuximab vedotin with CHP for CD30-expressing peripheral T-cell lymphomas
Clinical Trials & Observations Brief Report
Michelle A. Fanale, Steven M. Horwitz, Andres Forero-Torres, Nancy L. Bartlett, Ranjana H. Advani, Barbara Pro, Robert W. Chen, Andrew Davies, Tim Illidge, Mayur Uttarwar, Shih-Yuan Lee, Hong Ren, Dana A. Kennedy, Andrei R. Shustov
Blood (2018) 131 (19): 2120–2124.
Includes: Supplemental data
Five-Year Survival Results: Frontline Brentuximab Vedotin in Combination with CHP in Patients with CD30-Expressing Peripheral T-Cell Lymphomas
Michelle A. Fanale, MD, Steven M. Horwitz, MD, Andres Forero-Torres, MD, Nancy L. Bartlett, MD, Ranjana H. Advani, MD, Barbara Pro, MD, Robert W. Chen, MD, Andrew Davies, PhD, Tim M. Illidge, MDPhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R. Shustov, MD
Blood (2017) 130 (Supplement 1): 2790.
Four-Year Survival and Durability Results of Brentuximab Vedotin in Combination with CHP in the Frontline Treatment of Patients with CD30-Expressing Peripheral T-Cell Lymphomas
Michelle A Fanale, MD, Steven M Horwitz, MD, Andres Forero-Torres, MD, Nancy L Bartlett, MD, Ranjana H Advani, MD, Barbara Pro, MD, Robert W Chen, MD, Andrew J Davies, FRCP PhD, Tim Illidge, PhD, Mayur Uttarwar, Dirk Huebner, MD, Hong Ren, MD, Andrei R Shustov, MD
Blood (2016) 128 (22): 2993.